A human-mouse chimeric anti-Siglec-15 full-molecule IgG with neutralizing effect and its preparation method and application
A molecular and antibody technology, applied in the field of biopharmaceuticals, to achieve high binding activity and affinity, and good neutralizing properties
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Example 1: Siglec-15 extracellular domain peptide design
[0038] Siglec-15 has a total of 328 amino acids, and the extracellular region consists of an N-terminal V-set domain (A49-A165) containing a sialic acid binding site and a type 2 constant region (IgC2) region (A168-A251), in which IgV The region is the key site where Siglec-15 binds to Sialyl-Tn. Using Siglec-15A37-A180 amino acids as templates, the Overlap polypeptides were designed and named as A1-A12 and B1-B11, respectively. After peptide synthesis, a portion was mixed and coupled to OVA and KLH, respectively.
[0039] A1 HSSPAQRWSMQV B1 RWSMQVPPEVSA A2 PPEVSAEAGDAA B2 EAGDAAVLPCTF A3 VLPCTFTHPHRH B3 THPHRHYDGPLT A4 YDGPLTAIWRAG B4 AIWRAGEPYAGP A5 EPYAGPQVFRCA B5 QVFRCAAARGSE A6 AARGSELCQTAL B6 LCQTALSLHGRF A7 SLHGRFRLLGNP B7 RLLGNPRRNDLS A8 RRNDLSLRVERL B8 LRVERLALADDR A9 ALADDRRYFCRV B9 RYFCRVEFAGDV A10 EFAGDVHDRYE...
Embodiment 2
[0040] Example 2: Preparation of murine anti-Siglec-15 hybridoma cells
[0041] Customized recombinant Siglec-15 whole gene protein according to human Siglec-15 gene. Using this protein and OVA-conjugated mixed polypeptides as immunogens, pure-line BALB / c mice were immunized by subcutaneous injection in the abdomen at 100 μg / ml each time, a total of five times, of which the 1st, 3rd, and 5th times used recombinant Siglec- 15 Whole gene protein, mixed polypeptide coupled with OVA was used for the 2nd and 4th times. When the peripheral serum can detect positive serum with an OD greater than 2, cell fusion is performed, and the mixed polypeptide coupled with OVA is used for boosting immunization 3 days before fusion. On the day of fusion, the mouse spleen was taken, and a single-cell suspension was prepared in DMEM medium (GIBCO, USA), and in the presence of 50% PEG (PH 8.0), the spleen cells and SP2 / 0 mouse myeloma cells were fused, using HAT selective medium (98 ml of DMEM me...
Embodiment 3
[0042] Example 3: Screening, Straining and Identification of Murine Anti-Siglec-15 Antibodies
[0043] Enzyme-linked immunosorbent assay (ELISA) detection and screening were carried out according to the growth of hybridoma cells, and the specific method was shown below. The plates were coated with recombinant Siglec-15 protein, and the cells in the positive wells were cloned and cultured again. After three subcloning, the positive clones were determined. Then, the plate was coated with Siglec-15 mixed polypeptide conjugated with KLH to detect the positive clones. After all the monoclonal cells in the wells were detected as positive for Siglec-15-KLH and negative for KLH, several wells were taken to expand the culture and partially cryopreserved.
[0044] The ELISA method was used to screen the monoclonal antibodies that were positive for Siglec-15 but seronegative in normal mice. The specific methods are as follows:
[0045] (1) The chemically synthesized Siglec-15-KLH polyp...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com